NasdaqCM - Delayed Quote • USD
Aligos Therapeutics, Inc. (ALGS)
At close: 4:00 PM EDT
After hours: 4:44 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 2 | 2 | 2 | 2 |
| Avg. Estimate | -0.19 | -0.21 | -0.83 | -0.82 |
| Low Estimate | -0.19 | -0.21 | -0.84 | -0.99 |
| High Estimate | -0.19 | -0.21 | -0.83 | -0.65 |
| Year Ago EPS | -0.53 | -0.43 | -1.36 | -0.83 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 2 | 2 | 2 | 2 |
| Avg. Estimate | -- | -- | -- | -- |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | -- | -- | -- | -- |
| Year Ago Sales | 2.72M | 6.89M | 9.34M | -- |
| Sales Growth (year/est) | -- | -- | -- | -- |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -0.48 | -0.49 | -0.47 | -0.27 |
| EPS Actual | -0.53 | -0.43 | -0.41 | -0.22 |
| Difference | -0.05 | 0.06 | 0.06 | 0.05 |
| Surprise % | -10.40% | 12.20% | 12.80% | 18.50% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.19 | -0.21 | -0.83 | -0.82 |
| 7 Days Ago | -0.19 | -0.21 | -0.83 | -0.82 |
| 30 Days Ago | -0.19 | -0.21 | -0.83 | -0.82 |
| 60 Days Ago | -0.27 | -0.26 | -1.04 | -1.06 |
| 90 Days Ago | -0.39 | -0.37 | -0.96 | -1.01 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | ALGS | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 64.20% | -- | -- | 6.50% |
| Next Qtr. | 51.20% | -- | -- | 12.00% |
| Current Year | 39.00% | -- | -- | 5.30% |
| Next Year | 1.20% | -- | -- | 13.10% |
| Next 5 Years (per annum) | -- | -- | -- | 11.09% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Maintains | Piper Sandler: Overweight | 1/17/2023 |
| Upgrade | Piper Sandler: Neutral to Overweight | 1/6/2023 |
| Upgrade | Jefferies: Hold to Buy | 1/6/2023 |
| Maintains | SVB Leerink: Market Perform | 11/3/2022 |
| Downgrade | SVB Leerink: Outperform to Market Perform | 5/5/2022 |
| Maintains | SVB Leerink: Outperform | 3/23/2022 |
Related Tickers
CTMX CytomX Therapeutics, Inc.
1.5900
-0.62%
ASMB Assembly Biosciences, Inc.
12.65
-5.31%
SPRO Spero Therapeutics, Inc.
1.4600
+2.10%
ACHL Achilles Therapeutics plc
0.7600
-2.69%
EIGRQ Eiger BioPharmaceuticals, Inc.
2.6700
-12.17%
NXTC NextCure, Inc.
1.3500
+4.65%
GLPG.AS Galapagos NV
26.68
+0.45%
CLRB Cellectar Biosciences, Inc.
3.0300
+0.33%
TIL Instil Bio, Inc.
10.60
+2.02%
SPRB Spruce Biosciences, Inc.
0.7000
-0.14%